| Trial ID: | L4050 |
| Source ID: | NCT02611596
|
| Associated Drug: |
Ranolazine
|
| Title: |
Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Silent Myocardial Ischemia|Type 2 Diabetes
|
| Interventions: |
DRUG: Ranolazine|DRUG: Placebo
|
| Outcome Measures: |
Primary: hs cTnT, Does ranolazine decrease hs cTnT in subjects at high risk for silent myocardial ischemia?, 24 weeks|NT-pro-BNP, Does ranolazine decrease NT-pro-BNP in subjects at high risk for silent myocardial ischemia?, 24 weeks|hsCRP, Determine the degree of decrease of hs CRP in subjects in the ranolazine group., 24 weeks | Secondary: prevalence of hs cTnT > 99th percentile, Determine the prevalence of hs cTnT greater than the 99th percentile (0.014 ng/mL) in asymptomatic diabetic subjects with stable ischemic heart disease., 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: Walter Reed National Military Medical Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: OTHER
|
| Start Date: |
2016-11
|
| Completion Date: |
2019-11
|
| Results First Posted: |
|
| Last Update Posted: |
2017-05-17
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT02611596
|
